Package Insert: Information for the Patient
Espidifen 400 mg Granule for Oral Solution, Peppermint Flavor
Ibuprofen (Arginine)
Read this entire package insert carefully before starting to take this medication, as it contains important information for you.
1. What isEspidifenand for what it is used
2. What you need to know before starting to takeEspidifen
3. How to takeEspidifen
4. Possible adverse effects
5. Storage ofEspidifen
6. Contents of the package and additional information
Ibuprofen (arginine) belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs).
This medicine is used for the treatment of fever, the treatment of mild to moderate pain including migraine, the treatment of arthritis (inflammation of the joints, including those of the hands and feet, leading to swelling and pain), juvenile rheumatoid arthritis, osteoarthritis (a chronic disorder that causes cartilage damage), ankylosing spondylitis (inflammation affecting the joints of the spine), non-rheumatic inflammation, and primary dysmenorrhea (painful menstruation).
Do not take Espidifen:
Warnings and precautions
Consult your doctor before starting to take Espidifen:
Espidifenmay mask the signs of an infection, such as fever and pain. Consequently, it ispossible thatEspidifenmay delay the appropriate treatment of the infection, which may increasethe risk of complications. This has been observed in pneumonia caused by bacteria and in bacterial skin infections related to chickenpox. If you take this medication while you have aninfection and the symptoms of the infection persist or worsen, consult a doctor without delay.
This risk is higher when using high doses and prolonged treatment, in patients with a history of peptic ulcer disease, and in elderly patients. In these cases, your doctor may consider associating a stomach-protective medication.
It is essential to use the smallest dose that relieves or controls pain and not to take this medication for longer than necessary to control your symptoms.
Avoid concurrent administrationwith other NSAIDs, including those referred to as COX-2 inhibitors.
Be especially careful with Espidifen:
Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), generalized acute pustular psoriasis (PEGA), have been reported in association with ibuprofen treatment. Discontinue Espidifen treatment and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Precautions in elderly patients
Elderly patients have a higher frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal.
Cardiovascular precautions
NSAIDs, such as ibuprofen, may be associated with a small increase in the risk of heart attack or stroke, especially when used in high doses.
Do not exceed the recommended dose or treatment duration.
You should inform your doctor or pharmacist before taking Espidifen if:
Additionally, this type of medication may cause fluid retention, especially in patients with heart failure and/or high blood pressure.
Signs of allergic reaction to this medication, such as respiratory problems, facial and neck swelling (angioedema), and chest pain, have been reported. Stop using this medication immediately and contact your doctor or emergency medical services if you observe any of these signs.
Ibuprofen should be used with caution when administered to patients who have or have had asthma, bronchial asthma, chronic rhinitis, or allergic diseases, as ibuprofen has been reported to cause bronchospasm, urticaria, or angioedema in these patients.
Children and adolescents
There is a risk of kidney failure in dehydrated children and adolescents.
This medication is not recommended for children and adolescents weighing less than 40 kg or under 12 years old, as the ibuprofen dose contained is not suitable for the recommended dosage in this patient group.
Precautions during pregnancy and in fertile women
Due to the association of ibuprofen (arginine) type medications with an increased risk of congenital anomalies/abortions, it is not recommended to administer this medication during the first and second trimesters of pregnancy, except in cases where it is strictly necessary and advised by your doctor..
If you need treatment during this period or while trying to become pregnant, you should use the lowest dose for the shortest possible time.
If you take it for a few days from 20 weeks of gestation onwards, Espidifen may cause kidney problems in your baby that may lead to low amniotic fluid levels surrounding the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need treatment for a few more days, your doctor may recommend additional monitoring.
During the third trimester, the administration of ibuprofen (arginine) is contraindicated.
For fertile women, it should be noted that ibuprofen (arginine) type medications have been associated with a decrease in the ability to conceive.
Interference with analytical tests
If you are to undergo any diagnostic test (includingblood, urine, skin tests that use allergens, etc...) inform your doctor thatyou are takingthis medication, as it may alter the results.
Use of Espidifen with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Espidifen may affect or be affected by other medications. For example:
The following medications may interfere and, therefore, should not be taken together with Espidifen without consulting your doctor:
Other medications may also affect or be affected by Espidifen treatment. Therefore, you should always consult your doctor or pharmacist before using Espidifen with other medications.
Taking Espidifen with food, drinks, and alcohol
It is recommended to take the granulated ibuprofen (arginine) tablets with water or another liquid. You can take them alone or with food. In general, it is recommended to take it during meals or immediately after eating to reduce the possibility of stomach discomfort. Drinking alcohol during treatment may increase the risk of gastrointestinal side effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Espidifen should not be taken during pregnancy, especially during the third trimester (see section on precautions during pregnancy and in fertile women). It may cause kidney and heart problems in your baby. It may affect your tendency and that of your baby to bleed and make labor longer or more difficult than expected..
Small amounts of ibuprofen and its metabolites are excreted in breast milk. As no undesirable effects have been reported in the infant, it is usually not necessary to discontinue breastfeeding during short-term use at recommended doses.
Therefore, if you become pregnant or are breastfeeding, consult your doctor.
Driving and operating machinery
If you experience dizziness, vertigo, visual disturbances, or other symptoms while taking this medication, you should not drive or operate hazardous machinery. If you only take a single dose of ibuprofen (arginine) or take it for a short period, you do not need to take special precautions.
Espidifen contains aspartame, sucrose, butylated hydroxyanisole (E 320), and sodium
This medication contains 25 mg of aspartame in each packet. Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
This medication contains sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains 57 mg of sodium (main component of table salt/for cooking) in each packet. This corresponds to 2.85% of the recommended daily maximum sodium intake for an adult.
This medication may cause local reactions or irritation of mucous membranes because it contains butylated hydroxyanisole (E320).
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of treatment with Espidifen. Do not discontinue treatment beforehand, as this would not yield the expected results. Similarly, do not use this medication for a longer period than indicated by your doctor.
This medication is administered orally.
Patients with stomach discomfort should take the medication with milk or during/after meals.
Adults and adolescents
In adults and adolescents aged 12 to 18 years, one packet (400 mg) will be taken every 6 to 8 hours, depending on the severity of the condition and response to treatment.
In some cases, higher doses may be required, but in any case, it is recommended not to exceed the maximum daily dose of 2,400 mg in adults and 1,600 mg in adolescents aged 12 to 18 years.
Use in elderly patients
If you are over 60 years old, your doctor may prescribe a lower dose than usual. If so, the dose can only be increased once your doctor has confirmed that you tolerate the medication well.
Use in patients with kidney and/or liver disease
If you have kidney and/or liver disease, your doctor may prescribe a lower dose than usual. If so, take the exact dose prescribed by your doctor.
If you estimate that the action of Espidifen is too strong or too weak, inform your doctor or pharmacist.
Use in children
This medication is not recommended for use in children and adolescents weighing less than 40 kg or under 12 years old, as the ibuprofen dose contained is not suitable for the recommended dosage in this patient group.
If you take more Espidifen than you should
In case of overdose or accidental ingestion, consult a doctor or pharmacist immediately, go to the nearest hospital, or call the Toxicological Information Service (phone: 91.5620420) indicating the medication and the amount ingested, to inform yourself about the risk and ask for advice on the measures to be taken.
The symptoms of overdose may include nausea, stomach pain, vomiting (which may be bloody), gastrointestinal bleeding (see also section 4 below), diarrhea, headache, ringing in the ears, confusion, and tremors of the eyes. Agitation, drowsiness, disorientation, or coma may also occur. Occasionally, patients develop seizures. At high doses, somnolence, chest pain, palpitations, loss of consciousness, seizures (mainly in children), weakness, and dizziness, blood in the urine, low potassium levels in the blood, feeling cold, and respiratory problems have been reported. Additionally, the prothrombin time/INR may be prolonged, probably due to interference with the actions of circulating clotting factors. Acute renal failure and liver damage may occur. It is possible that asthma may worsen in asthmatics. Additionally, low blood pressure and difficulty breathing may occur.
In case of ingestion of significant amounts, activated charcoal should be administered. Gastric lavage may be considered if significant amounts have been ingested and within 60 minutes of ingestion.
If you forget to take Espidifen
Do not take a double dose to compensate for the missed dose.
If you forget to take your dose, take it as soon as you remember. However, if the time for the next dose is near, skip the missed dose and take the next dose at your usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The side effects of medicines like Espidifen are more common in people over 65 years old.
The incidence of side effects is lower in short-term treatments and if the daily dose is below the maximum recommended dose.
Frequencies are established according to the following classification: very common (can affect more than 1 in 10 patients); common (can affect up to 1 in 10 patients); uncommon (can affect up to 1 in 100 patients); rare (can affect up to 1 in 1,000 patients); very rare (can affect up to 1 in 10,000 patients); frequency unknown (cannot be estimated from available data).
The following side effects have been observed:
Infections and infestations
Very rare: Exacerbation of inflammatory conditions related to infection (for example, the development of necrotizing fasciitis), coinciding with the use of nonsteroidal anti-inflammatory drugs.
Nota: If signs of infection or worsening occur during treatment with ibuprofen, it is recommended to see a doctor immediately, if necessary to initiate anti-infective/antibiotic therapy.
Blood and lymphatic system disorders
Rare: Aplastic anemia (insufficiency of the bone marrow to produce different types of cells).
Very rare: Decreased platelets, decreased white blood cells (may manifest as frequent infections with fever, chills, or sore throat), decreased red blood cells (may manifest as difficulty breathing and pale skin), decreased granulocytes (a type of white blood cell that may predispose to infections), pancytopenia (deficiency of red, white, and platelet cells in the blood), agranulocytosis (very large decrease in granulocytes), hemolytic anemia (premature destruction of red blood cells). The first symptoms are: fever, sore throat, superficial ulcers in the mouth, pseudogripal symptoms, extreme fatigue, nasal and cutaneous bleeding. Prolonged bleeding time.
Immune system disorders
Uncommon:Allergic reaction, hypersensitivity reactions with skin rash and pruritus, as well as asthma attacks (possibly accompanied by a fall in blood pressure).
Rare: Anaphylaxis (generalized allergic reaction).
Very rare: Severe hypersensitivity reactions (these may be characterized by swelling of the face, tongue, and larynx with bronchospasm, dyspnea, tachycardia, and hypotension that may include potentially fatal shock).
Nota: In the event of these symptoms, which may occur with the first use, immediate assistance from a doctor is required.
Mental disorders
Uncommon: Insomnia, anxiety, restlessness.
Rare: Psychotic reaction, nervousness, irritability, depression, confusion, disorientation.
Nervous system disorders
Common: Fatigue or drowsiness, headache, dizziness or sensation of instability.
Uncommon: Insomnia, excitement, irritability.
Rare: Paresthesia (numbness, tingling, burning, etc. more frequent in hands, feet, arms, or legs).
Very rare: Aseptic meningitis. In most cases where aseptic meningitis has been reported with ibuprofen, the patient suffered some form of autoimmune disease (such as systemic lupus erythematosus or other collagen diseases) which was a risk factor. The symptoms of aseptic meningitis observed were neck stiffness, headache, nausea, vomiting, fever, or disorientation.
Eye disorders
Uncommon: Visual disturbances.
Rare: Abnormal or blurred vision.
Frequency unknown: Papilledema (inflammation of the optic nerve).
Ear and labyrinth disorders
Common: Vertigo.
Uncommon: Ringing or buzzing in the ears.
Rare: Hearing difficulty.
Cardiac disorders
Medicines like Espidifen may be associated with a moderate increase in the risk of suffering a heart attack ("myocardial infarction") or stroke.
Very rare: Palpitations, heart failure.
Frequency unknown: Cardiac failure,chest pain, which may be a sign of a potentially severe allergic reaction called Kounis syndrome.
Vascular disorders
Edema (fluid retention), hypertension, and heart failure have also been observed in association with treatments with ibuprofen (arginine) type medications.
Very rare: Hypertension.
Frequency unknown: Arterial thrombosis.
Respiratory, thoracic and mediastinal disorders
Uncommon: Asthma, worsening of asthma, bronchospasm, dyspnea (breathing difficulty).
Frequency unknown: Irritation of the throat.
Gastrointestinal disorders
The most common side effects that occur with medicines like Espidifen are gastrointestinal: Peptic ulcers, gastrointestinal bleeding, perforations (in some cases fatal, especially in elderly patients.
Common: Gastrointestinal disorders such as pyrosis (heartburn, reflux), abdominal pain, nausea, vomiting, flatulence, diarrhea, constipation, and mild gastrointestinal bleeding that may cause anemia in exceptional cases.
Uncommon: Gastrointestinal ulcers, potentially with bleeding and perforation, stomatitis, exacerbation of colitis and Crohn's disease, melena (blood in stool), gastritis.
Rare: Vomiting with blood.
Very rare: Inflammation of the esophagus, pancreatitis, intestinal stenosis.
Frequency unknown: Anorexia.
Hepatobiliary disorders
Rare: Liver damage, hepatitis (inflammation of the liver), abnormalities of liver function, and jaundice (yellowing of the skin and eyes).
Skin and subcutaneous tissue disorders
Common: Skin rash.
Uncommon: Redness of the skin, itching or swelling of the skin (angioedema, urticaria), purpura (purple spots on the skin).
Rare: Anaphylactic reaction.
Very rare: Medicines like Espidifen may be associated, in very rare cases, with severe blistering reactions such as Stevens-Johnson syndrome (widespread erosions affecting the skin and two or more mucous membranes and lesions of purple color, preferably on the trunk) and toxic epidermal necrolysis (erosions in mucous membranes and painful lesions with necrosis and detachment of the epidermis). Hair loss, erythema multiforme (skin lesion),. Exceptionally, severe skin infections and complications in the soft tissue may occur during chickenpox.
Frequency unknown:Phototoxicity, aggravation of skin reactions.Severe skin reactions known as DRESS syndrome may occur. Symptoms of DRESS syndrome include: skin rash, lymph node inflammation, and elevated eosinophils (a type of white blood cell),generalized red scaly rash, with bumps under the skin and blisters, located mainly in skin folds, trunk, and upper limbs, accompanied by fever at the beginning of treatment (generalized acute pustular exanthema). Stop taking Espidifen if you experience these symptoms and seek medical attention immediately. See section 2.
Renal and urinary disorders
Rare: Hematuria (blood in urine).
Very rare: Edema (signs that may indicate kidney disease, which sometimes may include renal insufficiency); renal tissue damage (papillary necrosis), increased serum uric acid concentration.
Based on the experience with nonsteroidal anti-inflammatory drugs in general, cases of interstitial nephritis, nephrotic syndrome, and renal insufficiency cannot be ruled out.
General disorders and administration site conditions
Very rare: Exacerbation of inflammatory conditions during infectious processes.
Frequency unknown: Edema.
Investigations
Rare: Alteration of liver function tests.
Frequency unknown: Alteration of renal function tests.
Until now, severe allergic reactions have not been reported with Espidifen, although they cannot be ruled out. The manifestations of this type of side effect could be fever, skin rash, abdominal pain, severe headache, nausea, vomiting, angioedema, swelling of the face, tongue, and throat, difficulty breathing, asthma, palpitations, hypotension, or shock.
If any of the following side effects occur, discontinue treatment and seek medical attention immediately:
Discontinue treatment with Espidifen and seek medical attention immediately if you notice any of the following symptoms:
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date shown on the packaging after the abbreviation CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medicines at your local SIGRE collection point at your usual pharmacy. Ask your pharmacist how to dispose of unused packaging and medicines. By doing so, you will help protect the environment.
Composition of Espidifen
The active ingredient is ibuprofen. Each sachet contains 400 mg of ibuprofen (as 770 mg of ibuprofen arginine).
The other components (excipients) are: aspartame (E951), sucrose, sodium hydrogen carbonate, sodium saccharin, peppermint aroma and anise aroma (contains butyl hydroxyanisole (E 320)). See section 2. “Espidifen contains aspartame, sucrose, butyl hydroxyanisole (E 320) and sodium”
Appearance of Espidifen and contents of the packaging
Oral granule solution, white in color.
Each package contains 30 sachets with granules.
Marketing Authorization Holder
Zambon, S.A.U.
Maresme, 5. Polígono Can Bernades-Subirà
08130 Sta. Perpètua de Mogoda (Barcelona)
Spain
Responsible for Manufacturing
Zambon, S.p.A.
Via della Chimica, 9
36100 Vicenza
Italy
or
Zambon, S.A.U.
Maresme, 5. Polígono Can Bernades-Subirà
08130 Sta. Perpètua de Mogoda (Barcelona)
Spain
Last review date of this leaflet:November 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.